KIROMIC BIOPHARMA INC (KRBP) Stock Overview
USA - NASDAQ:KRBP - US4976342042 - Common Stock
KRBP Key Statistics, Chart & Performance
The current stock price of KRBP is 1.45 USD. In the past month the price decreased by -38.56%. In the past year, price decreased by -86.7%.
KRBP Latest News, Press Relases and Analysis
KRBP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About KRBP
Company Profile
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
Company Info
KIROMIC BIOPHARMA INC
7707 Fannin St., Suite 140
Houston TEXAS 77054 US
CEO: Maurizio Chiriva-Internati
Employees: 31
Phone: 18329684888.0
KIROMIC BIOPHARMA INC / KRBP FAQ
Can you describe the business of KIROMIC BIOPHARMA INC?
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
What is the stock price of KIROMIC BIOPHARMA INC today?
The current stock price of KRBP is 1.45 USD. The price decreased by -8.23% in the last trading session.
What is the dividend status of KIROMIC BIOPHARMA INC?
KRBP does not pay a dividend.
What is the ChartMill technical and fundamental rating of KRBP stock?
KRBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists KRBP stock?
KRBP stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for KIROMIC BIOPHARMA INC?
KIROMIC BIOPHARMA INC (KRBP) operates in the Health Care sector and the Biotechnology industry.
Is KIROMIC BIOPHARMA INC (KRBP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KRBP.
KRBP Technical Analysis
KRBP Financial Highlights
Over the last trailing twelve months KRBP reported a non-GAAP Earnings per Share(EPS) of -47.46. The EPS increased by 24.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |